CDDF ANNUAL CONFERENCE 2023

"CHALLENGES IN CLINICAL TRIAL PERFORMANCE"

6 - 8 FEBRUARY 2023

HYBRID CONFERENCE

NOORDWIJK AAN ZEE, NETHERLANDS

PROGRAM

→ WWW.CDDF.ORG

WELCOME NOTE

On behalf of the Cancer Drug Development Forum, its partners, and my colleagues from the organizing committee, Ruth Plummer, Chitkala Kalidas, Debbie Mackanzie, Christopher Abegunde, Natacha Bolaños and Kim Lyerly, I would like to welcome you to the 2023 CDDF Annual Conference on challenges in clinical trial performance. The conference is planned as hybrid meeting and will give the opportunity to participants to attend both onsite and on-line. We have intensively invested in video technology and the adaptation of formats to ensure a high-quality experience also for on-line participants; however we encourage our participants to join us onsite for great networking opportunities.

The program has been built to facilitate participation from many parts of the globe, although the focus is on Europe and North America. We will have discussions on topics such as diversity in clinical data, decentralised clinical trials, treatment-dose and schedule optimization, as well as an entire session on difficulties faced in their early career by those involved in clinical trials. We will also briefly revisit the outcomes and take-home messages of the CDDF workshops and joint events that took place in 2022.

We are excited with the great speakers who have accepted our invitation, and incredibly thankful for the support of all the stakeholders in building the program. Many clinical researchers, pharmaceutical industry representatives, patient advocacy representatives, and regulators, will join us in undoubtedly lively discussions.

We are looking forward to the discussions with you, they are at the core of our mission to facilitate oncology drug development.

Prof. Jaap Verweij
Cancer Drug Development Forum Managing Director
CDDF Annual Conference Programme chair

EVENT OUTLINE

The 2023 Annual Meeting will cover various aspects that will be important in future performance of clinical trials aiming at drug registration. It will cover the challenges related to population diversity, the practical aspects of decentralised trials, the difficulties faced in their early career by those involved in clinical trials, and will dwell on some regulatory topics.

PROGRAMME COMMITTEE

- Jaap Verweij (CDDF, NL)
- Ruth Plummer (CDDF, UK)
- Kim H. Lyerly (AAADV, US)
- Natacha Bolaños (Lymphoma Coalition, ES)
- Debbie Mackanzie (AstraZeneca, US)
- Chitkala Kalidas (Bayer, US)
- Christopher Abegunde (Eisai, UK)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA and national agencies), pharmaceutical industry, HTAs and patient advocates.

HYBRID CONFERENCE AND VENUE

The conference will be held at the Alexander Hotel (Oude Zeeweg 63, 2202 CJ) in Noordwijk aan Zee, NL. However, participation online via the Brella event platform will also be possible. Only approved participants will receive the link and log-in details to access the virtual platform.

MEETING SECRETARIAT

Cancer Drug Development Forum (CDDF) - info@cddf.org - www.cddf.org

c/o BLSI Clos Chapelle-aux-Champs 30, 1200 Brussels, Belgium

PROGRAMME

DAY 1 – MONDAY 6 FEBRUARY 2023

12:00 - 12:50	Lunch
12:50 - 13:00	Welcome Note

SESSION 1: DIVERSITY IN CLINICAL DATA

Session Chairs: Axel Glasmacher (CDDF, DE) - Sushmita Sen (Roche, CH)

13:00 - 13:20	Diversity issues from the perspective of health technology assessment Carole Longson (NICE, UK)
13:20 - 13:40	Patient perspective Gilliosa Spurrier-Bernard (MPNE, MelanomeFrance, FR)
13:40 - 14:00	Reflections on how to ensure diversity in clinical practice and clinical trials Marie von Lilienfeld-Toal (Jena University Hospital, DE)
14:00 - 14:20	Ensuring data diversity in big data platforms and building AI algorithms David Cahané (Owkin, FR)
14:20 - 15:00	Panel discussion
15:00 - 15:30	Coffee break

SESSION 2: REFLECTIONS ON CDDF WORKSHOPS IN 2022

Session Chairs: John Smyth (University of Edinburgh, UK)

15:30 - 15:35	Session opening
15:35 - 16:00	Workshop on MRD and ct/DNA (20') + Q&A (5') Axel Glasmacher (CDDF, DE)
16:00 - 16:25	Workshop on patient access and engagement (20') + Q&A (5') Mark Lawler (CDDF, UK)
16:25 - 16:50	Workshop on histology independent drug development (20') + Q&A (5') Ruth Plummer (CDDF, UK)
16:50 - 17:15	AAADV-ASCO-CDDF joint workshop on global collaboration (20') + Q&A (5') Kim H. Lyerly (AAADV, US)
18:30 - 22:30	Offsite dinner (Breakers Beach House)

DAY 2 – TUESDAY 7 FEBRUARY 2023

SESSION 3: WHAT I SHOULD HAVE ASKED WHEN I STARTED MY CARREER IN CANCER DRUG DEVELOPMENT

Session Chairs: Debbie Mackanzie (AstraZeneca, UK); Kim H. Lyerly (AAADV, US)

10:30 - 10:35	Session opening
10:35 - 10:55	Industry Perspective Theresa Kolben (Bayer, DE)
10:55 - 11:15	Biologist perspective Steve Wedge (Newcastle University, UK)
11:15 - 11:35	Clinician perspective Stefan Symeonides (CDDF, UK)
11:35 - 11:55	Patient Perspective Bettina Ryll (Melanoma Patient Network Europe, SE)
11:55 - 12:30	Panel discussion
12:30 - 14:45	Offsite lunch (Nomade Beach Club)

SESSION 4: DECENTRALISED CLINICAL TRIALS

Session Chairs: Chitkala Kalidas (Bayer, US); Ruth Plummer (CDDF, UK)

15:00 - 15:05	Session opening
15:05 - 15:25	Medicine trials in 2050: In-clinic, or decentral Jaap Verweij (CDDF, NL)
15:25 - 15:45	Process of decentralised clinical trial Jeff Evans (Glasgow Experimental Cancer Medicine Centre, UK)
15:45 - 16:05	Industry Perspective Victoria Chiou (AstraZeneca, US)
16:05 - 16:45	Panel discussion Guest panelist: Manfred Grote (Bayer, DE)
19:00 - 22:00	Onsite dinner (hotel restaurant)

DAY 3 – WEDNESDAY 8 FEBRUARY 2023

SESSION 5: TREATMENT-DOSE AND SCHEDULE OPTIMIZATION

Session Chairs: Jaap Verweij (CDDF, NL)

10:55 - 11:00	Session opening
11:00 - 11:20	FDA Project Optimus Mirat Shah (FDA, US)
11:20 - 11:40	The EMA Cancer Medicine Forum and dose optimization Denis Lacombe (EORTC, BE)

11:40 - 12:00	De-escalation of immunotherapy. The example of MOIO phase III French clinical trial Gwenaelle Gravis (Institut Paoli-Calmettes, FR)
12:00 - 12:20	The Optimal Cancer Care Alliance (OCCA) view and experience Daniel Goldstein (Davidoff Cancer Center, Rabin Medical Center, IL)
12:20 - 13:00	Panel discussion and farewell
13:00 - 13:30	Onsite lunch (take away possible)